Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HAPPY SUNDAY!
Sorry for the complaint but could we update our news releases and relevant page content please....as well as correct grammatical errors please?
FOX BUISENESS VIDEO INTERVIEW
correct spelling of business
Enjoy the day!
3BB
Outstanding post....thank you.
Outstanding post Rio.
https://citronresearch.com/wp-content/uploads/2020/10/Compass-Pathways-The-Platform-Mental-Health-Company-50-Years-in-the-Making.pdf
Although this company is unrelated, I thought I'd post to show the advances and awareness psilocybin is finally experiencing in the mainstream.
Best to all!
3BB
GO RVVTF!!
Buys are higher than sells currently.
Well done Uncle GG
Nice post Karin!
Just heard president is about to head to hospital for a better of tests. State that it’s just extra precautions. I hope he is ok b
We caught this yesterday.
Agree...well done Notos!
Jane was buying in the .55 range last week
I was wondering....saw her on the board buying last week. I did not realize impact of her presence.
Excellent post JB....enjoyed the entire read. Thank you!
Hello All,
Accumulation over the past 6 weeks or so...AUG 6 to present. Tried to post a graph picture but for some reason it wouldn't take. Steadfast and patience is key with this investment.
JMHO
Yes they’re private.
https://finance.yahoo.com/news/relief-neurorx-announce-partnership-global-050000886.html
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
PR Newswire PR Newswire•September 21, 2020
- RLF-100™ (Aviptadil) is in advanced stages of phase 2b/3 development in the US
- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) has been reported under FDA Emergency Use IND authorization at multiple clinical sites
GENEVA, Switzerland and RADNOR, Pa., Sept. 21, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide. The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis. They have agreed that NeuroRx will lead commercialization in the United States, Canada, and Israel, while Relief will lead commercialization in Europe and the rest of the world. Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel, 85/15 (in favor of Relief) in Europe, and 80/20 (in favor of Relief) in all other territories.
The two companies have now taken steps to increase manufacturing of the aviptadil drug substance and are in the final stages of contracting with a fill/finish manufacturer, along with a national distribution partner. By January 2021, Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100. The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020. The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks.
As part of their agreement, Relief and NeuroRx intend to pursue the issuance of trademarks on RLF-100. NeuroRx shall prosecute such trademarks in the U.S., Canada and Israel, while Relief shall prosecute trademarks in all other territories.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We are pleased to reach this agreement with NeuroRx, a partner we believe is best suited to ensure rapid clinical development as well as timely and expedient interaction with regulatory authorities in what is likely to be the most important market for the drug, the United States. We are looking forward to collaboratively and productively working together in order to maximize the value of the overall franchise for our shareholders and get this potentially life-saving drug to patients as swiftly as possible."
Jonathan C. Javitt, Chief Executive Officer of NeuroRx, added: "As the global pandemic continues to devastate families and communities, our small team is encouraged by the early promise we have seen in Sami Said's scientific legacy and we are working around the clock to bring this drug to patients."
About VIP in Lung Injury
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, which is critical to the transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.
COVID-19-related death is primarily caused by Respiratory Failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Continue reading
Very good points....I'm looking forward to the next few weeks/months. The DD certainly puts forth many internal positives and maintain a very bullish outcome IMHO.
Thank you for your feedback as well. Always enjoy your posts.
Enjoy!
3BB
Thank you!
From Yahoo Board
Posted 6 hours ago - Credit to BOGO
Deductively, try this theory: Dan Troy is the former Chief Legal Counsel to the FDA. He is now a present board member on NeuroRX. Mancef Slaoui present head of Operation Warp Speed was the former head of Glaxo Smith Klein’s vaccine department. Dan Troy, used to be Chief Legal Counsel for Glaxo Smith Klein and the Head of Business Development for Glaxo. Dan Troy is on the Board for NeuroRX. Glaxo Smith Klein is one of the 3 largest inhaler producers in the World. Who might the partner be who has been tapped for inhalers? We also know that there exists a storage of Avaptadil. Might we be the one’s the President referenced when he said we will be ready to go by November?? Certainly, by years end. Relief had formerly partnered with BIOGEN for the production of Avaptadil. Dr. Javitt’s repute is high and mighty, well known in Government ties and to Big Pharma. Care to share your thoughts that GSK is one partner, and that this drug, which has been determined safe for dozens of years, will roll once the entity used to house it, is formed? There are too many coincidences. With that said, Big Pharma has a lot of money to make their own transactions succeed and to stop others. That too is at play.
Lol....thanks! Didn’t realize.....
Trades listed are completely red indicator all sells....what’s up?
You nailed it!!
GM All,
Ditto Guy - very good observation. Thank you for pointing this out.
Enjoy!
3BB
Petition to Terminate Trading Suspension -
3. On April 1, 2020, Ohio Governor Mike DeWine requested that manufacturers aid the state in repurposing their manufacturing facilities to produce difficult to obtain supplies to
respond to the COVID-19 pandemic.1
4. In response to the Governor’s request, the Company launched production of its Oxithymol disinfectant on April 16, 2020 (the “April Release”).
5. Oxithymol uses a hydrogen peroxide solution that meets the CDC’s approved guidelines, as an ingredient in its production.
6. On April 21, 2020, the Company learned that the EPA registration process for Oxithymol would be several months. In order to accommodate the request of Governor DeWine, 1 https://repurposingproject.com/
3 the Company contracted with Essential Water Solutions, Inc. to bottle its EPA-registered Oxy Blast 50 Hydrogen Peroxide Solution (“Blast 50”) in its EPA-registered facilities.
7. Blast 50 can be applied using the Oxi Thyme atomizing ULV/HPLV fogging system.
8. In April 2020, the Company began, and as of the date hereof is still pursuing, the necessary registration with the EPA regarding its Oxythymol product.
9. In a press release by the Company on July 17, 2020, the Company announced revenue growth contributable, in part, to growth in sales of the Oxi Thyme system (the “July Release”).
10. The Company is unaware of any the purchase or sale of any of its securities by any insider, officer, director, etc.
Re-Post from DD Police on the Yahoo Board. Worthwhile and good analysis. Thank you for taking the time to put this together...DD Police.
DD POLICE - 8 hours ago
A lot of confusion on capital structure of Relief Therapeutics. I have done some DD and below are my conclusions. The Six Exchange website is our source for info, but unfortunately it is very poorly represented and not up to date. That said, I have done my best and believe I am correct in my findings. Hopefully our Swiss Friends on the Cash.Ch forums can read this, as they seem confused as well:
https://www.ser-ag.com/en/resources/notifications-market-participants/significant-shareholders.html#/shareholder-details/TAK9200037
GEM does not own 64% of Relief.
From the link above GEM owns 707,475,186 shares which represents 30.93% of voting rights.
707,475,186/30.93% = 2,287,342,987 shares outstanding. We know based on latest PR that Share count is at 2.534b shares and not 2.287b. So Six is using outdated share count here.
Add up all of the options in the link above that GEM owns and you get another 733,325,334 shares after exercise.
Six also lists another potential 25,781,293 shares if Relief exercises it’s SSF (Share Subscription Facility) with GEM at a price of 0.488CHF. RLF doesn’t have to use this facility.
707,475,186 + 733,325,334 + 25,781,293 = 1,466,581,813 potential shares outstanding the GEM may eventually hold
Now here is where Six math makes no sense at all, but it is how they do it. After exercising options, they assume the share count doesn’t increase. In my experience when warrants get exercised a company will typically issue new shares (authorized shares are used here for example). But let’s play along with Six Exchange:
1,466,581,813/2,287,342,987 = 64.117%
This is where Six gets it’s 64.11%
And it is entirely incorrect!
Here is more realistic math. I can’t guarantee it is correct, because I don’t know all of the contracts they signed on these warrants and options, but using an assumption that all of these warrants and options are standard contracts (very likely) here it goes:
We know from latest PR that share count is 2.534b (this includes the 66.667m shares that GEM took from Yves for 0.01HCF that are not included on Six yet, since they say they weren’t delivered yet according to Six).
As I previously posted; all options and warrants amount to 695m, including GEM (who has 733m -66.7m = roughly 667m of those 695m). The rest belongs to management team and others.
https://www.ser-ag.com/de/resources/notifications-market-participants/significant-shareholders.html#/shareholder-details/TAK8R00056
This confirms the numbers at 695,576,325 warrants/options outstanding (after the 66.7m Yves Options got exercised) of which GEM holds 666,658,667 (The Devil is in the details ?? )
Fully diluted share count stands at 3.23b. This is an important number and that is why I talked about it in my past posts (may have used slightly different number due to rounding error). It is the number I use to determine market cap and future value of the company.
GEM fully diluted, i.e. after exercising all options will have 1,466,581,813 shares (as calculated above)
Total Share Count Fully Diluted will be 695,576,325 + 2,534,168,581 = 3,229,744,906 (same 3.23b number above)
All options/warrants have strike price under 0.04 CHF and vast majority at 0.01 CHF, so all are guaranteed to get exercised.
GEM fully diluted, after all options/warrants are exercised will have 1,466,581,813 shares. But we have to exclude the 25,781,293 shares from the SSF that Relief may never use (not certain like option/warrant exercise):
1,466,581,813 – 25,781,293 = 1,440,800,520 shares fully diluted for GEM
1,440,800,512/3,229,744,906 = 44.61% ownership of the entire company.
Apparently, there are Six Exchange rules where if a shareholder owns more than 33.33% (one third) of a company’s shares outstanding it has to make an offer to purchase the entire company. But in 2019, Relief past a statute that anyone can buy more than 33.33% of it’s shares and not have to make an offer to buy out the whole company (sounds like it was tailormade for GEM).
There you have it. GEM does not own 64% of the company. It currently owns:
707,475,186 + 66,666,667 = 774,141,853 shares after the Yves called shares get delivered.
Current share ownership:
774,141,853/2,534,168,581 = 30.55%
Once again, fully diluted will be 44.61%
Good read...thank you rain.
Keep it real people...referencing to both sides. The last few days worth of posting seems to really deter form the true opportunities that this company has to offer. Whether positive or negative this board is "no bueno" as of late.
JMHO....again keep it real.
3bb
Trump is on...
Outstanding summarization mc67. Thank you for posting.
Very well put PB.
Would it not be feasible that the US would provide some grant monies?
Delayed but latest Swiss market price .60....gain of .10
Good morning RLF crew...Looking forward to a nice two days of trading before the weekend!
....Me three very long term hold!
Thanks "mytoessmell" from yahoo RLF yahoo board
The significant clinical improvement seen in these 21 patients treated with intravenous RLF-100 (Aviptadil), is consistent with the finding that VIP not only blocks viral replication in the pulmonary epithelium but creates a “bystander effect” whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. This highly specific role of VIP in the lung may be key to combating the lethal effects of SARS-CoV-2 infection. A randomized prospective trial is underway, which will attempt to demonstrate that intravenous RLF-100 improves survival, oxygenation, and clinical course of Critical COVID-19 with respiratory failure. The independent Data Monitoring Committee of that trial has conducted the first unblinded look at the study data and identified no safety signals. Moreover, the DMC has determined that the study is not futile in its objective to identify a statistically significant difference between aviptadil and placebo in remission from COVID-19 respiratory failure.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
Found on the RLF yahoo page.
Abstract
Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect Alveolar Type II cells by blocking replication of the SARS-CoV-2 virus, inhibiting cytokine synthesis, preventing cytopathy, and upregulating surfactant production. RLF-100™ (aviptadil), a synthetic form of VIP has been granted Fast Track Designation for treating Critical COVID-19 with Respiratory Failure and is currently in phase 2/3 placebo-controlled trials.
Methods: Case series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP. Sixteen patients were treated with mechanical ventilation and five with extracorporeal membrane oxygenation (ECMO).
Results: So far, 19 of 21 patients have survived. Improved radiographic appearance was seen in both lungs of 17 patients and in one lung of 2 patients. A mean 292% increase in PaO2:FiO2 ratio was seen with complete remission from respiratory failure in 9 patients and ongoing improvement in 10. Seven patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. Three of 5 patients on ECMO have been decannulated and two have been discharged. A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen with corresponding decrease in C-reactive protein. A median 4 point reduction in the NIAID Ordinal Scale was observed (P<.01).
Comment: The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.
Note: Funding: Funding:Research support was provided by the Cavendish Impact Foundation. Clinical trial funding was provided by Relief Therapeutics Holdings, AG, Geneva, which holds intellectual property related to the pharmacologic use of Aviptadil.
Conflict of Interest: Author JCJ is employed bya pharmaceutical company that is currently conducting clinical trials of RLF-100in patients with COVID-19 and has a financial interest in the outcome of those clinical trials. Author MJJ was paid for medical writing by NeuroRx, Inc. Author JGY has received funding as an investigator for RLF-100 through his institution.
Ethical Approval: Human subjects protection was overseen by the Institutional Review Board (IRB) of the Houston Methodist Hospital.
Keywords: VIP, vasoactive intestinal peptide, aviptadil, SARS-CoV-2, corona virus, COVID-19, respiratory failure, IL6, ARDS
one of them is a very conservative Republican congressman / MD....Andy Harris, US Congressman
Great news....Prayers that he recovers.
Well wishes to both him and his family...
I really hope he gets what he needs. Good thing he's in the Houston area...approval should be expedited.
Prayers....
Thank you so much....I appreciate the kind words.
We will all be rewarded...this is a tremendous opportunity!
GLTA!!